Institutional Investors' Divergent Views Drive Ginkgo Bioworks Holdings Trading Activity

2024-03-12

At the meeting held to discuss the quarter ending December 31, 2023, it was revealed that Ginkgo Bioworks Holdings (DNA) was actively traded by both hedge funds and ETFs. A total of 332 hedge funds were holding 1,255,232,860 DNA shares, with 112 hedge funds purchasing shares and 102 selling shares during the last quarter. Notably, 20 hedge funds decided to double their positions in DNA, while 4 hedge funds opted to sell at least 90% of their DNA shares.

On the ETF front, there were 21 ETFs holding 206,939,423 DNA shares. Among the top institutional holders of DNA shares were Baillie Gifford & Co, ARK Investment Management LLC, Viking Global Investors LP, Vanguard Group Inc, and BlackRock Inc.

During the meeting, it was highlighted that the most optimistic institutions regarding DNA included ARK Investment Management LLC, Norges Bank, State Street Corp, Lingotto Investment Management LLP, and Jane Street Group, LLC. Conversely, the most pessimistic institutions on DNA were identified as Morgan Stanley, Squarepoint Ops LLC, HRT Financial LP, Baillie Gifford & Co, and Citadel Advisors LLC.

The data presented at the meeting, sourced from sharkstracker.com, provided a data-driven perspective on the market, offering valuable insights into the trading activity and sentiment surrounding Ginkgo Bioworks Holdings.